Analyst Research

Report Title Price
Provider: Streetwise Reports
$46.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S And GlaxoSmithKline Plc Receives Approval in Japan


Monday, 25 Mar 2013 02:14am EDT 

Genmab A/S and GlaxoSmithKline Plc announced the approval of Arzerra (ofatumumab) by the Japanese Ministry of Health, Labor and Welfare (MHLW) for use in patients with relapsed / refractory CD20-positive chronic lymphocytic leukemia (CLL). The approval triggers a milestone payment of DKK 20 million from GSK to Genmab. 

Company Quote

46.28
 --
25 Nov 2014